Medidata and Sanofi Vaccines extend collaboration
February 7, 2024Research and Development Immunology, Medidata, Sanofi Vaccines, eCOA
Medidata and Sanofi Vaccines have announced a collaboration utilising Medidata electronic clinical outcome assessment (eCOA) within vaccine trials, building on …
Novartis to acquire MorphoSys AG for €2.7bn
February 6, 2024Business Services Novartis, Pharmacy, acquisition, morphosys
Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, or €68 per share. The …
Vertex announces positive results from trial for cystic fibrosis combination treatment
February 6, 2024Research and Development Chronic Diseases, Vertex pharmaceuticals, clinical trial, combination treatment, cystic fibrosis
Vertex Pharmaceuticals has announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor programme, the company’s phase 3 programme for the treatment of …
Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets
February 5, 2024Business Services Cialis, Eli Lilly, Pharmacy, Zuellig Pharma, acquisition
Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) and Alita (Pemetrexed) from Eli …
Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment
February 5, 2024Medical Communications EMA, Oncology, Regeneron, linvoseltamab, multiple myeloma
Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorisation Application (MAA) for …
Vivet Therapeutics gains €4.9m for gene therapy development
February 2, 2024Research and Development CTX, Neurology, Vivet Therapeutics, funding, gene therapy
Vivet Therapeutics has announced that it has received €4.9m financing from the French Government for the advanced development of a …
AstraZeneca shares results from phase 3 trial of acoramidis in adults with ATTR-CM
February 2, 2024Research and Development ATTR-CM, AstraZeneca, Cardiology, acoramidis, clinical trial
AstraZeneca has announced positive high-level results from the phase 3 trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) …
NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL
February 1, 2024Medical Communications AbbVie, DLBCL, NICE, Oncology, lymphoma
AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment …
FDA grants ODD to Revolo Biotherapeutics’ eosinophilic esophagitis treatment
February 1, 2024Medical Communications FDA, ODD, Pharmacy, Revolo Biotherapeutics, eosinophilic esophagitis
Revolo Biotherapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, …
MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment
January 31, 2024Medical Communications GSK, MHRA, Omjjara, Oncology, myelofibrosis, splenomegaly
GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Omjjara (momelotinib) in …
Regeneron forms Regeneron Cell Medicines with acquisition of 2seventy bio
January 31, 2024Business Services 2seventy bio, Pharmacy, Regeneron, Regeneron Cell Medicines, acquisition
Regeneron Pharmaceuticals has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio to acquire the …
FDA clears IND for Gracell Biotechnologies’ phase 1 clinical trial for multiple myeloma treatment
January 30, 2024Research and Development FDA, Gracell Biotechnologies, Oncology, clinical trial, multiple myeloma
Gracell Biotechnologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, …
Oxford Biomedica acquires ABL Europe for €15m
January 30, 2024Business Services ABL Europe, Oxford BioMedica, Pharmacy, acquisition
Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut Mérieux. This follows announcements on …
EMA to review GSK’s Arexvy for RSV prevention in adults aged 50-59
January 29, 2024Medical Communications Arexvy, EMA, Infections and infestations, RSV
GSK has announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of …
Vergent Bioscience shares phase 2 data for VGT-309
January 29, 2024Research and Development Oncology, VGT-309, Vergent Bioscience, lung cancer
Vergent Bioscience has announced new data from a phase 2 trial of VGT-309, the company’s investigational tumour-targeted fluorescent imaging agent. …
MHRA approves Mounjaro for diabetes and weight management
January 26, 2024Medical Communications Diabetes, MHRA, Mounjaro, weight management
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a four-dose version of the diabetes …
AbbVie invests $223m in Singapore manufacturing site
January 26, 2024Manufacturing and Production AbbVie, Pharmacy, Singapore, manufacturing
AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing facility. This will create more …
Haleon recalls cough syrups due to microbial contamination
January 25, 2024Medical Communications Haleon, Pharmacy, cough syrup, microbial contamination
The US Food and Drug Administration (FDA) has shared an announcement from Haleon detailing the voluntary recall of eight lots …
Alphamab Oncology and 3DMedicines enter licensing agreement with Glenmark Speciality
January 25, 2024Medical Communications 3DMedicines, Alphamab Oncology, Glenmark Speciality, Oncology, envafolimab
Alphamb Oncology and 3DMedicines have announced that they have entered into a license agreement with Glenmark Speciality, a subsidiary of …
Futura Medical appoints Roy Davis as non-executive director
January 25, 2024Business Services Futura Medical, Roy Davis, appointment, non-executive director
Futura Medical has announced the appointment of Roy Davis as non-executive director effective immediately. Roy has extensive commercial experience in …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
